Distinct claudin expression characterizes BRCA1-related breast cancer

Histopathology

Volumn 65, Issue 6, 2014, Pages 814-827

  Heerma van Voss, Marise R ^b   van Diest, Paul J ^b   Smolders, Yvonne H C M ^b   Bart, Joost ^a,b   van der Wall, Elsken ^b   van der Groep, Petra ^b  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BRCA1 protein; Claudins; Familial breast cancer

Indexed keywords

BRCA1 PROTEIN; CLAUDIN 1; CLAUDIN 3; CLAUDIN 4; CLAUDIN 6; CLAUDIN 7; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; CLAUDIN; TUMOR MARKER;

ARTICLE; BRCA1 RELATED BREAST CANCER; BREAST CANCER; BREAST EPITHELIUM CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; GENE OVEREXPRESSION; GERMLINE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR VOLUME; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; MUTATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CLAUDINS; FEMALE; GENES, BRCA1; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84919398004     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12490     Document Type: Article

References (62)

1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007; 25; 1329-1333.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 2010; 363; 1938-1948.
3. van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell. Oncol. (Dordr.) 2011; 34; 71-88.
4. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003; 100; 8418-8423.
5. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005; 65; 9603-9606.
6. Hoevel T, Macek R, Swisshelm K et al. Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids. Int. J. Cancer 2004; 108; 374-383.
7. Mullin JM. Potential interplay between luminal growth factors and increased tight junction permeability in epithelial carcinogenesis. J. Exp. Zool. 1997; 279; 484-489.
8. Myal Y, Leygue E, Blanchard AA. Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers. J. Biomed. Biotechnol. 2010; 2010; 956897.
9. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011; 5; 5-23.
10. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73; 643-651.
11. van DP, Baak JP, Matze-Cok P et al. Reproducibility of mitosis counting in 2, 469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum. Pathol. 1992; 23; 603-607.
12. Armes JE, Egan AJ, Southey MC et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998; 83; 2335-2345.
13. The Medical Research Involving Human Subjects Act (Wet medisch-wetenschappelijk onderzoek met mensen, WMO; text in Dutch). In Burgerlijk wetboek, 1998: Available at: http://wetten.overheid.nl/BWBR0009408/geldigheidsdatum_16-12-2013.
14. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ 2002; 325; 648-651.
15. van der Groep P, Bouter A, van der Zanden R et al. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 2004; 96; 712-713; author reply 714.
16. van der Groep P, van Diest PJ, Menko FH et al. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J. Clin. Pathol. 2009; 62; 926-930.
17. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295; 2492-2502.
18. Choi J, Jung WH, Koo JS. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol. Histopathol. 2012; 27; 1481-1493.
19. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979; 6; 65-70.
20. Heerma van Voss MR, van der Groep P, Bart J et al. Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls. BMC Cancer 2010; 10; 145.
21. Heerma van Voss MR, van der Groep P, Bart J et al. Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell. Oncol. (Dordr.) 2011; 34; 3-10.
22. Blanchard AA, Ma X, Dueck KJ et al. Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 2013; 13; 268.
23. Kulka J, Szasz AM, Nemeth Z et al. Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathol. Oncol. Res. 2009; 15; 59-64.
24. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009; 69; 4116-4124.
25. Gerhard R, Ricardo S, Albergaria A et al. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast 2012; 21; 354-360.
26. DelloRusso C, Welcsh PL, Wang W et al. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol. Cancer Res. 2007; 5; 35-45.
27. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006; 6; 186.
28. Birks DK, Kleinschmidt-DeMasters BK, Donson AM et al. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2010; 20; 140-150.
29. Ushiku T, Shinozaki-Ushiku A, Maeda D et al. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology 2012; 61; 1043-1056.
30. Kubista M, Rosner M, Kubista E et al. Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene 2002; 21; 4747-4756.
31. Furuta S, Jiang X, Gu B et al. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc. Natl Acad. Sci. USA 2005; 102; 9176-9181.
32. Liu S, Ginestier C, Charafe-Jauffret E et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc. Natl Acad. Sci. USA 2008; 105; 1680-1685.
33. Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009; 15; 907-913.
34. Blanchard AA, Skliris GP, Watson PH et al. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 2009; 454; 647-656.
35. Arabzadeh A, Troy TC, Turksen K. Changes in the distribution pattern of Claudin tight junction proteins during the progression of mouse skin tumorigenesis. BMC Cancer 2007; 7; 196.
36. Ricardo S, Gerhard R, Cameselle-Teijeiro JF et al. Claudin expression in breast cancer: high or low, what to expect? Histol. Histopathol. 2012; 27; 1283-1295.
37. Romero A, Prat A, Garcia-Saenz JA et al. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. Clin. Transl. Oncol. 2013; 16; 386-394.
38. Morohashi S, Kusumi T, Sato F et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int. J. Mol. Med. 2007; 20; 139-143.
39. Kominsky SL, Vali M, Korz D et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am. J. Pathol. 2004; 164; 1627-1633.
40. Tokes AM, Kulka J, Paku S et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res. 2005; 7; R296-R305.
41. Furuse M, Hata M, Furuse K et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 2002; 156; 1099-1111.
42. Swisshelm K, Machl A, Planitzer S et al. SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily. Gene 1999; 226; 285-295.
43. Kramer F, White K, Kubbies M et al. Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum. Genet. 2000; 107; 249-256.
44. Kleinberg L, Holth A, Fridman E et al. The diagnostic role of claudins in serous effusions. Am. J. Clin. Pathol. 2007; 127; 928-937.
45. Szasz AM, Tokes AM, Micsinai M et al. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin. Exp. Metastasis 2011; 28; 55-63.
46. Liu Y, Wang L, Lin XY et al. Anti-apoptotic effect of claudin-1 on TNF-alpha-induced apoptosis in human breast cancer MCF-7 cells. Tumour Biol. 2012; 33; 2307-2315.
47. Martinez-Estrada OM, Culleres A, Soriano FX et al. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem. J. 2006; 394; 449-457.
48. Lanigan F, McKiernan E, Brennan DJ et al. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int. J. Cancer 2009; 124; 2088-2097.
49. Ebihara C, Kondoh M, Hasuike N et al. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. J. Pharmacol. Exp. Ther. 2006; 316; 255-260.
50. Kominsky SL, Tyler B, Sosnowski J et al. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res. 2007; 67; 7977-7982.
51. Vincent T, Neve EP, Johnson JR et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat. Cell Biol. 2009; 11; 943-950.
52. Papageorgis P, Lambert AW, Ozturk S et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res. 2010; 70; 968-978.
53. Zhang K, Yao HP, Wang MH. Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility. Carcinogenesis 2008; 29; 552-559.
54. Cao D, Polyak K, Halushka MK et al. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res. 2008; 10; R91.
55. Xu X, Jin H, Liu Y et al. The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas. Diagn. Pathol. 2012; 7; 33.
56. Wu Q, Liu Y, Ren Y et al. Tight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinoma. Eur. J. Cancer Prev. 2010; 19; 186-194.
57. Quan C, Lu SJ. Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays. Carcinogenesis 2003; 24; 1593-1599.
58. Osanai M, Murata M, Chiba H et al. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Sci. 2007; 98; 1557-1562.
59. Yafang L, Qiong W, Yue R et al. Role of estrogen receptor-alpha in the regulation of claudin-6 expression in breast cancer cells. J. Breast Cancer 2011; 14; 20-27.
60. Kominsky SL, Argani P, Korz D et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003; 22; 2021-2033.
61. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 2009; 106; 13820-13825.
62. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12; R68.